A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

This study is testing a drug called siltuximab to treat serious side effects — cytokine release syndrome (CRS) and immune cell-related brain inflammation (ICANS) — that can happen after CAR-T cell therapy in multiple myeloma patients. CAR-T therapy uses a patient's own immune cells to fight cancer, but can sometimes cause dangerous inflammation. **You may be eligible if:** - You are 18 or older - You have multiple myeloma - You developed CRS or ICANS (grade 1 or higher) after receiving CAR-T cell therapy **You may NOT be eligible if:** - Your kidney function is significantly reduced (creatinine clearance below 30 mL/min) - Your blood counts (platelets, white blood cells, or hemoglobin) are too low - Your liver enzyme or bilirubin levels are too high - You have serious heart disease or had a heart attack in the last 6 months - You have severe infections or other serious health conditions Talk to your doctor to see if this trial is right for you.